MDDI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Medtech in a Minute: Another Deal Bites the Dust, Telemedicine Changes the Game, and More

Pressed for time? Here's the medtech news you need most, in one minute or less.

Your time is valuable, so we've drilled down the three most important medtech stories from the past week. But feel free to click the headline to read beyond the blurb.

Image by OpenClipart-Vectors on Pixabay

Another Deal Bites the Dust

Citing a negative market impact from COVID-19, Alphatec backed out of its agreement to acquire EOS Imaging. While the deal is no longer feasible as contemplated, Alphatec said it is open to a strategic collaboration, if EOS is willing. Earlier this month, Organovo killed a proposed merger with Tarveda Therapeutics, but not because of the pandemic. That decision was prompted by indecisive scientific data on Organovo's part.

Telemedicine Is Changing the Diabetes Game

Telemedicine is emerging as the hero technology during COVID-19. In the diabetes space, the technology is enabling new patient access to continuous glucose monitoring devices during a time when physician office visits have drastically declined. For companies like Dexcom, this shift is expected to offset some of the impact the company initially saw in new patient opportunities after social distancing measures took effect.

Are Patients Dying Because of Deferred TAVR Procedures?

Edwards Lifesciences CEO Mike Mussallem mentioned during the company's first-quarter earnings call that some patients have died because their transcatheter aortic valve replacement (TAVR) procedure was postponed due to COVID-19. The company does, however, expect TAVR procedure volumes to be back to normal by the fourth quarter.

Filed Under
500 characters remaining